Navigation Links
Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Date:2/10/2012

Thomas for his many years of valuable service to Silence and wish him well with his future endeavours. I am delighted that Tony has agreed to take on the CEO role. He has impressed us since joining and I am sure he will continue to do so."

Tony Sedgwick, newly promoted Chief Executive Officer, added: "Since joining Silence Therapeutics in September 2011, I have been excited by the Company and the opportunities that lie ahead.   We have a unique proprietary position in RNAi therapeutics and their delivery. I am confident that this will be further strengthened and will be the basis upon which investors and pharmaceutical partners alike will take an increasing interest in this Company. We have already strengthened the business development team with the appointment of Dr Georg Buchner who will now take full responsibility for business development. The Company's pipeline including  Atu027  is making good progress and is endorsed by external partners. I look forward to taking on the role of Chief Executive Officer and working with the staff at Silence to strengthen the Company's pipeline. Over the next few years, I intend to increase the commercial focus of the Company, harness the  RNAi therapeutics  opportunity and, as a result, create substantial'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Additional Listing
2. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
3. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
4. Silence Therapeutics Provides Corporate and Development Update
5. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
6. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
7. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
8. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... (Amex: ETC ) ("ETC" or the "Company") ... two BARA-MED(R) XD,Monoplace Hyperbaric Chambers at Christus Spohn, ... Christi, Texas, in 1905 and is,the largest and ... The,facility offers South Texans a full range of ...
... SAN DIEGO, Sept. 23 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced that Douglas ... Vice,President, Endocrinology Clinical Development., "I am thrilled ... caliber,and achievement to the Halozyme leadership team. He ...
... Development of Novel Infectious ... Disease Diagnostic Platform -, WOBURN, ... a $4.5 million equity investment from BD (Becton, Dickinson,and Company) ... development of a novel infectious disease diagnostic,platform. The collaboration will ...
Cached Biology Technology:Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers 3Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 2Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 3Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 4U.S. Genomics Inc. Receives $4.5 Million Investment from BD 2U.S. Genomics Inc. Receives $4.5 Million Investment from BD 3
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
(Date:11/10/2014)... store shelves in early 2010, and people have used ... can be tossed into a washing machine without ever ... convenience, though, has come with risks for young children. ... Hospital found that from 2012 through 2013, U.S. poison ... 6 years of age swallowing, inhaling, or otherwise being ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2
... of ice, a minimally invasive interventional radiology treatment called ... damage, according to data being presented at the Society ... Orleans. "Cryoneurolysis could have big implications for the ... be unbearable and is very difficult to treat," said ...
... WEST ORANGE, N.J.The State of Spinal Cord Injury: Latest ... Recovery will be held on Wednesday, April 17, 2013, ... Pleasant Valley Way, West Orange, N.J. This special Grand ... Cord Injury System (NNJSCIS) and the Spinal Cord Injury ...
... have revealed the mechanism that causes a slime to ... antibiotics. When under threat, some bacteria can shield ... biofilm. It is made up of communities of bacteria ... cause dental plaque and sinusitis; in healthcare, biofilms can ...
Cached Biology News:Freezing nerves knocks pain out cold 2The State of Spinal Cord Injury Grand Rounds 2Secrets of bacterial slime revealed 2
... T2-04 is an ultra-compact pump available in single ... and ideal for use in portable air and ... this pump works well in environments where DC ... compact size are critical., Offers ultra-compact size, ...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Lone Wolf valve has the highest performance ... available on the market. This VSO valve ... and ensures maximum accuracy., Achieves rapid, ... and patient comfort. , Maintains ideal flow ...
Biology Products: